Charles River offers a broad range of syngeneic tumor models with well-characterized responses to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1 and anti-CTLA-4), making us the ideal partner to advance your immuno-oncology pipeline.
Models With Profile
|Colon||Colon26, CT26, MC38|
|Lung||KLN 205, Lewis Lung, Madison109|
Models Without Profile*
|Breast||EMT-6-BRCA1(−/−), EMT-6-BRCA1(+/−), 4T1-BRCA1(+/−)|
|Leukemia||C1498, L1210, P388|
* Note: Although these models have not yet been profiled for response to current standards of care, tumor growth curve data is available.
|SYNGENEIC MODEL DATA|
Access our syngeneic model data including check point inhibitor and whole exome sequencing (WES).